COMMUNIQUÉS West-GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
02/02/2026
FOSTER CITY, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of February 1, 2026 [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/02/2026
CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly- [...]
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/02/2026
LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on [...]
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
02/02/2026
SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12 [...]
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/02/2026
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Cronos Group Launches Premium Lord Jones® Brand in Israel, Advancing Borderless Product Strategy
02/02/2026
TORONTO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON; TSX: CRON) (“Cronos” or the “Company”), a leading global cannabinoid company, today announced the launch of its Lord Jones® premium cannabis [...]
Michigan Integrative Health Expands Stem Cell Therapy Services to Welcome Canadian Patients
02/02/2026
Detroit, MI, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Michigan Integrative Health Stem Cells , a leading provider of stem cell therapy and regenerative medicine in Shelby Township, Michigan, announces the expansion of its [...]
Logan University Begins Accepting Applications for Physician Assistant (PA) Program
02/02/2026
Inaugural Cohort Scheduled to Start in January 2027 ST. LOUIS, Feb. 02, 2026 (GLOBE NEWSWIRE) -- As a leader in integrated healthcare education, Logan University is expanding its degree offerings with the Master of [...]
EssilorLuxottica: Full-Year 2025 Results Conference Call Invitation
02/02/2026
Full-Year 2025 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr [...]
SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
02/02/2026
Ghent, Belgium, Feb. 02, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 2 February 2026, 6 : 00 pm CET Ghent, Belgium, 2 February 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) ( [...]
IBA – Share buyback
02/02/2026
Louvain-la-Neuve, Belgium, February 2 nd , 2026 – 6PM CET – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today the launch of a share buyback program, [...]
IBA – Rachat d’Actions Propres
02/02/2026
Louvain-la-Neuve, Belgique, 2 février 2026 – 18h00 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules, annonce aujourd’hui le lancement d’un programme de rachat d’ [...]
KabaFusion and Nautic Partners Announce Completion of Significant Growth Investment
02/02/2026
LEXINGTON, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- KabaFusion (the “Company”), a nationally recognized leader in home and alternative site infusion, and Nautic Partners (“Nautic”) announced today that Nautic has [...]
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
02/02/2026
CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss 1 . CagriSema achieved superior HbA 1c reduction of up to 1.91%- [...]
H.H.C. Group Releases White Paper on Independent Reviews in an AI-Driven Claims Environment
02/02/2026
ROCKVILLE, Md., Feb. 02, 2026 (GLOBE NEWSWIRE) -- H.H.C. Group (H.H.C.) , the leader in reducing healthcare costs by providing high-quality cost containment through claim negotiation, repricing and independent review [...]
EssilorLuxottica: Full-Year 2025 Results Conference Call Invitation
02/02/2026
Full-Year 2025 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr [...]
CorMedix Therapeutics Announces Share Repurchase Program
02/02/2026
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [...]
Quotient Therapeutics Appoints Seasoned Life Sciences Executive, Susan Keefe, as Chief Financial Officer
02/02/2026
CAMBRIDGE, Mass. and CAMBRIDGE, United Kingdom, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has appointed [...]
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
02/02/2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: [...]

Pages